129 related articles for article (PubMed ID: 29189239)
1. New Indication for Ibrutinib.
Aschenbrenner DS
Am J Nurs; 2017 Dec; 117(12):22. PubMed ID: 29189239
[No Abstract] [Full Text] [Related]
2. New Indication for Ruxolitinib.
Aschenbrenner DS
Am J Nurs; 2022 Jan; 122(1):20. PubMed ID: 34941588
[TBL] [Abstract][Full Text] [Related]
3. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Jaglowski SM; Blazar BR
Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
Rahmat LT; Logan AC
Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
[TBL] [Abstract][Full Text] [Related]
5. New approved indication for ibrutinib.
Aschenbrenner DS
Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
[No Abstract] [Full Text] [Related]
6. FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
King-Kallimanis BL; Wroblewski T; Kwitkowski V; De Claro RA; Gwise T; Bhatnagar V; Farrell AT; Kluetz PG
Qual Life Res; 2020 Jul; 29(7):1903-1911. PubMed ID: 32100182
[TBL] [Abstract][Full Text] [Related]
7. FDA grants accelerated approval for ibrutinib for CLL.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
[No Abstract] [Full Text] [Related]
8. Ibrutinib approved for the treatment of mantle cell lymphoma.
Small S
Clin Adv Hematol Oncol; 2013 Dec; 11(12):808. PubMed ID: 25016625
[No Abstract] [Full Text] [Related]
9. Ibrutinib approved for mantle cell lymphoma.
Cancer Discov; 2014 Jan; 4(1):OF1. PubMed ID: 24402946
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Mazzucchelli M; Cairoli R; Montillo M
Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
[TBL] [Abstract][Full Text] [Related]
11. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing acute intestinal graft-versus-host disease by a non-invasive method: transabdominal ultrasonography and colour doppler imaging.
Spadea M; Saglio F; Pessolano R; Opramolla A; Calvo PL; Fagioli F
Lancet; 2021 Sep; 398(10306):1170. PubMed ID: 34563295
[No Abstract] [Full Text] [Related]
13. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Hershkovitz-Rokah O; Pulver D; Lenz G; Shpilberg O
Br J Haematol; 2018 May; 181(3):306-319. PubMed ID: 29359797
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders.
Cabras MG; Angelucci E
Expert Opin Pharmacother; 2015; 16(18):2715-8. PubMed ID: 26549294
[TBL] [Abstract][Full Text] [Related]
17. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
Dowdall M
Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
[No Abstract] [Full Text] [Related]
18. [Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
Bruhn C
Med Monatsschr Pharm; 2014 Jul; 37(7):268-9. PubMed ID: 25065170
[No Abstract] [Full Text] [Related]
19. Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Bagcchi S
Lancet Oncol; 2015 May; 16(5):e204. PubMed ID: 25892147
[No Abstract] [Full Text] [Related]
20. Riociguat approved for pulmonary hypertension.
Traynor K
Am J Health Syst Pharm; 2013 Nov; 70(22):1960. PubMed ID: 24173000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
